Avadel Pharmaceuticals (AVDL) EPS (Weighted Average and Diluted) (2016 - 2020)
Historic EPS (Weighted Average and Diluted) for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q4 2020 value amounting to -$0.04.
- Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) rose 9652.15% to -$0.04 in Q4 2020 from the same period last year, while for Dec 2020 it was $0.12, marking a year-over-year increase of 10579.25%. This contributed to the annual value of -$0.12 for FY2020, which is 9434.09% up from last year.
- According to the latest figures from Q4 2020, Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.04, which was up 9652.15% from -$0.2 recorded in Q3 2020.
- Avadel Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.68 during Q2 2017, with a 5-year trough of -$1.71 in Q4 2018.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.2 (2020), whereas its average is -$0.2.
- In the last 5 years, Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 50666.67% in 2017 and then tumbled by 76619.95% in 2018.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.11 in 2016, then crashed by 272.01% to -$0.2 in 2017, then plummeted by 766.2% to -$1.71 in 2018, then grew by 28.8% to -$1.22 in 2019, then surged by 96.52% to -$0.04 in 2020.
- Its EPS (Weighted Average and Diluted) was -$0.04 in Q4 2020, compared to -$0.2 in Q3 2020 and $0.44 in Q2 2020.